NCT00195819 - Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

June 30, 2009

Conditions

Ankylosing Spondylitis

Interventions

BIOLOGICAL

adalimumab (D2E7)

Adalimumab 40 mg every other week (eow)

BIOLOGICAL

placebo

Placebo every other week (eow)

Trial Locations (9)

Site Ref # / Investigator 74, Calgary

Site Ref # / Investigator 70, Edmonton

Site Ref # / Investigator 79, Vancouver

Site Ref # / Investigator 64, Winnipeg

Site Ref # / Investigator 78, St. John's

Site Ref # / Investigator 75, Toronto

Site Ref # / Investigator 63, Toronto

Site Ref # / Investigator 62, Toronto

Site Ref # / Investigator 77, Saskatoon